Myriad Fails to Meet Endpoint With Alzheimer's Drug Candidate

After disappointing Phase III trial results, Myriad is discontinuing its development of Flurizan for Alzheimer’s disease.

In the 18-month study of Flurizan (tarenflurbil), patients failed to meet significant markers in cognition and functions of daily living, the study’s primary endpoints.

The company said the discontinuation of Flurizan will reduce its pharmaceutical development spending and enable it to achieve profitability next year.